Xenon Pharmaceuticals (XENE) Change in Cash (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Change in Cash data on file, last reported at $346.7 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $346.7 million, up 1430.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $429.2 million (up 643.08% YoY), and the FY2025 annual result was $56.5 million, up 1051.8% from the prior year.
• Change in Cash grew to $346.7 million in Q1 2026 per XENE's latest filing, from $94.6 million in the prior quarter.
• Over five years, Change in Cash peaked at $346.7 million in Q1 2026 and troughed at -$266.5 million in Q3 2022.
• A 5-year average of $21.8 million and a median of $12.3 million in 2023 frame the typical range for Change in Cash.
• On a YoY basis, Change in Cash climbed as much as 5113.77% in 2022 and fell as far as 5562.14% in 2022.
• A 5-year view of Change in Cash shows it stood at -$46.2 million in 2022, then soared by 206.1% to $49.1 million in 2023, then increased by 12.27% to $55.1 million in 2024, then jumped by 71.8% to $94.6 million in 2025, then surged by 266.3% to $346.7 million in 2026.
• Business Quant data shows XENE's Change in Cash at $346.7 million in Q1 2026, $94.6 million in Q4 2025, and -$30.9 million in Q3 2025.